microdosing retatrutide daily Retatrutide—A Game Changer in Obesity Pharmacotherapy People are 'microdosing' weight-loss drugs.

Studies suggest that up to 25% of weight lost during treatment with GLP-1 agonists may come from lean body mass, including muscle

The MHRA advises monitoring for signs of dehydration and AKI when these side effects are prominent

The company is also expanding manufacturing capacity to meet surging prescriptions, helping protect its dominant market share

Clinical Insights for Rheumatology Providers For patients with rheumatic disease, several important themes are emerging: Osteoarthritis: Early evidence shows clinically meaningful improvements in knee and hip OA symptoms among patients who achieve significant weight loss with GLP-1 agents

IGF-1 LR3 According to Roberts, there are currently no human studies specifically focused on the efficacy of IGF-1 LR3 for muscle growth